Conceptus — Q2 2010 Earnings Presentation
30 slides from Conceptus's earnings presentation, Aug 5, 2010
Slide 1: Conceptus Inc. Quarterly Financial Results Second Quarter 2010
Conceptus Inc. Quarterly Financial Results Second Quarter 2010 Exhibit 99.2
Slide 2: Safe Harbor
Safe Harbor Except for the historical information contained herein, the matters discussed in this presentation include forward-looking statements, the accuracy of which is subject to risks and uncertainties. These forward-looking statements include discussions regarding projected net sales and net i
Slide 3: 2010 Outlook
2010 Outlook Mark Sieczkarek, President and Chief Executive Officer
Slide 4: Key Issues
$14 $4 $2 mm Key Issues mm mm Physician Office Visits Currency Physician Metrics 1. Macro issue: Physician Office Visits 2. Macro issue: Currency 3. Company-specific issue: Physician Metrics Recent $20mm decrease in FY’10 net sales guidance* due to: *On July 8, 2010, the Company updated guidance, in
Slide 5: Macro Issue: Physician Office Visits
1. Macro Issue: Physician Office Visits Impact: $14mm lost sales vs. previous 2010 guidance Impact of weak economy greater than anticipated Lingering effects of unemployment and loss of insurance coverage (COBRA) or patients switching to Medicaid Enrollment in high-deductible health insurance plans
Slide 6: Reduced Physician Office Visits
Reduced Physician Office Visits (1) IMS Data provided by Credit Suisse Healthcare Daily, May data published on June 23, 2010 General physician office visits were down 5-10% in 1H’10 (1) . We expect this trend to continue for 2H’10. Previous guidance incorporated a flat 1H’10 and 5-10% increase in 2H
Slide 7: Impact on the Industry
Impact on the Industry Market observations of economy and reduced physician office visits: July 29, 2010, Wall Street Journal: “Americans Cut Back on Visits to Doctor.” Physician visits and hospital admissions are dropping this year, according to Thomson Reuters' healthcare business, which surveys d
Slide 8: Non-Urgent Procedure Challenges
Non-Urgent Procedure Challenges Patient Perspective: Physician Perspective: • Permanent birth control is non-urgent • Subject to deductibles • Standard of care performed in ORs is higher cost • Acceptable alternatives As a non-urgent, high-cost procedure performed by primary care physician, our Essu
Slide 9: Macro Issue: Currency
2. Macro Issue: Currency Impact: $4mm lost sales vs. previous 2010 guidance 90% of international sales are euro denominated Greater international growth means greater impact Modeled $1.20 exchange rate for remainder of FY’10; previously modeled $1.35 for FY’10 International business on plan in units
Slide 10: Company-Specific Issue: Physician Metrics
3. Company-Specific Issue: Physician Metrics Impact: $2mm lost sales vs. previous 2010 guidance Growth in physician metrics impacted We expected: Competition targeting our accounts We did not expect: Significant resources allocated to defend our customer base and re-educate our physicians on Essure’
Slide 11: Essure: Long Term Efficacy Will Win
Essure: Long Term Efficacy Will Win Competitor has “trial window” time period before commercial performance reduces opportunity Based on field observations, competitor’s product is performing no better than its clinical trial statistics, resulting in failures to occlude and pregnancies Peer-reviewed
Slide 12: Our Priorities: Control the Controllable
Our Priorities Solution Control the Controllable Solution Solution Accelerate new physician adoption of Essure procedure Implement leaner cost structure through discretionary cuts Re-deploy assets to energize market growth: “back-to- basics” strategy
Slide 13: Second Quarter 2010 Financials
Second Quarter 2010 Financials Greg Lichtwardt Executive Vice President, Operations and Chief Financial Officer
Slide 14: Q2'10 Snapshot
Q2’10 Snapshot Gross Margin (%) Non-GAAP (1) EPS Operating Margin (%) GAAP EPS Net Sales ($mm) Q2’09 Q2’10 Q2’09 Q2’10 Q2’09 Q2’10 Q2’09 Q2’10 Q2’09 Q2’10 $0.08 $33.0 79.8% 80.2% $36.8 3.1% 3.8% ($0.02) ($0.01) $0.11 (1) See GAAP to non-GAAP reconciliation in appendix Company guidance for Q2’10: Net
Slide 15: Increasing Diversification through International Sales
26.0 28.0 Worldwide Sales 18.8 20.1 7.0 8.9 Q2'09 Q2'10 Domestic International Increasing Diversification through International Sales 9.8 13.2 Q2'09 Q2'10 Domestic International Q2’10 Net Sales (in million $) Q2’10 Units (in thousands) : 33.3 28.6 $36.8 $33.0 The difference between international uni
Slide 16: U.S. Physician Metrics
U.S. Physician Metrics Q2’10 Q1’10 Q4’09 Q3’09 Current Period Activity: Physicians entering preceptorship Physicians becoming certified Physicians transitioning to office Physician Base In preceptorship 3,486 3,434 3,417 3,425 Certified and in hospital 3,128 2,956 2,793 2,848 Certified and in office
Slide 17: Q2'10 Results
Q2’10 Results Q2’10 Q2’09 Y/Y Change Q1’10 Q/Q Change Net Sales $36.8 $33.0 11.5 % $33.4 10.5% Gross Profit Margin 80.2% 79.8% nm 80.8% nm Operating Expenses $28.1 $25.3 11.0% $27.7 1.5% Other Income / (Expense) ($1.6) ($1.5) nm ($1.5) nm Tax Provision $0.1 $0.08 nm $0.1 nm NEAT ($0.3) ($0.6) nm ($2
Slide 18: Q2'10 GAAP vs. Non-GAAP EPS
Q2’10 GAAP vs. Non-GAAP EPS Non-GAAP EPS $0.11 Amortization of intangibles Stock-based compensation $0.02 $0.06 $0.04 Amortization of non-cash items for convertible notes ($0.01) GAAP EPS See GAAP to non-GAAP reconciliation in Appendix ($291) $808 $1,802 $1,215 $3,534 Actual amount in $ thousands: Q
Slide 19: Balance Sheet
Balance Sheet Cash & cash equivalents Investments and put option A/R, inventories & other current assets PP&E Intangible and other assets Goodwill Total assets ASSETS 21.5 69.6 28.8 10.6 26.7 14.8 172.0 61.7 43.5 25.7 9.8 29.1 17.3 187.1 6/30/10 A/P & other accrued ST liabilities Line of credit Othe
Slide 20: Guidance
Guidance Q3’09A FY’09A Q3’10E FY’10E Net Sales $33mm to $34mm $143mm to $145mm $34.2 $131.4mm Gross Profit Margin 81.5% 81.5% 85.3% (1) 81.7% Operating Expenses $24mm $103mm $21.2mm $92.7mm Net Income $1.1mm to $1.9mm $6.8mm to $8.5mm $6.2mm $7.9mm GAAP EPS $0.03 to $0.06 $0.21 to $0.26 $0.20 $0.25
Slide 21: Market & Opportunity
Market & Opportunity Mark Sieczkarek, President and Chief Executive Officer
Slide 22: Hysteroscopic Market Expansion
Hysteroscopic Market Expansion Q3’09 Q4’09 Q1’10 Q2’10 +34% +35% +31% +22% Despite economy, market (1 ) net sales growth continues Y/Y (1) Market includes Essure and competition
Slide 23: Multi-Billion Dollar Market
Multi-Billion Dollar Market Our future market: Tubal ligations (2) : 643,000 Our current addressable market “Sweet Spot” Essure: 30,000 Permanent birth control procedures each year 700,000 In millions Base of 38 million women (1) 2006-08 CDC report, Data from the National Survey of Family Growth, pu
Slide 24: Long-Term Value Proposition
Long-Term Value Proposition Significant untapped U.S. market International market share continues to grow – Asia-Pacific untapped Essure procedure is “gold standard” – 99.8% effective based on 4-year clinical data – Only birth control method with zero pregnancies in clinical trials – Bilateral place
Slide 25: Strategy to Achieve Standard of Care
Strategy to Achieve “Standard of Care” Control the Controllable: – Re-deploy assets to energize market growth: “back-to-basics” strategy – Accelerate new physician adoption of Essure procedure – Implement leaner cost structure through discretionary expense cuts Strive to increase demand through pati
Slide 26: Conceptus' Inc.
Conceptus' Inc.
Slide 27: Conceptus' Inc.
Conceptus' Inc.
Slide 28: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation Reconciliation of Reported Net loss and Loss Per Share to Non-GAAP Net Income and Earnings Per Share 2010 2009 2010 2009 Net loss, as reported (291) $ (555) $ (2,642) $ (4,891) $ Adjustments to net loss: Amortization of intangibles (a) 1,627 Stock-based compensation (
Slide 29: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation Reconciliation of Forward-Looking Guidance For Non-GAAP Financial Measures From To From To GAAP Guidance 0.03 $ 0.06 $ 0.21 $ 0.26 $ Estimated Non-GAAP Guidance Amortization of intangibles (a) 0.02 $ 0.02 $ 0.10 $ 0.10 $ Stock-based compensation (b) 0.06 $ 0.06 $ 0.24
Slide 30: Thank You
Thank You CC-2462 05AUG10F